NCT01428453 - A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

October 1, 2011

Primary Completion Date

February 4, 2013

Study Completion Date

February 18, 2013

Conditions

Alzheimer's Disease

Interventions

DRUG

250mg rilapladib

Experimental Drug

DRUG

placebo

Placebo comparator

Trial Locations (30)

1113

GSK Investigational Site, Sofia

1431

GSK Investigational Site, Sofia

1478

GSK Investigational Site, Lørenskog

12004

GSK Investigational Site, Castellon

16132

GSK Investigational Site, Genoa

20122

GSK Investigational Site, Milan

25125

GSK Investigational Site, Brescia

26122

GSK Investigational Site, Oldenburg in Holstein

28006

GSK Investigational Site, Madrid

28832

GSK Investigational Site, Achim

28905

GSK Investigational Site, Getafe/Madrid

30559

GSK Investigational Site, Hanover

37134

GSK Investigational Site, Verona

44787

GSK Investigational Site, Bochum

44791

GSK Investigational Site, Bochum

44892

GSK Investigational Site, Bochum

48903

GSK Investigational Site, Baracaldo/Vizcaya

50935

GSK Investigational Site, Cologne

61348

GSK Investigational Site, Bad Homburg

63755

GSK Investigational Site, Alzenau in Unterfranken

72076

GSK Investigational Site, Tübingen

73479

GSK Investigational Site, Ellwangen

89081

GSK Investigational Site, Ulm

M3B 2S7

GSK Investigational Site, Toronto

J9A 1K7

GSK Investigational Site, Gatineau

J1H 1Z1

GSK Investigational Site, Sherbrooke

00185

GSK Investigational Site, Rome

08014

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, L'Hospitalet de Llobregat

se-141 86

GSK Investigational Site, Stockholm